CNBX (CNBX Pharmaceuticals) Net Margin %: 0.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals Net Margin %?

CNBX Pharmaceuticals CNBX +33.33% Net Margin % is 0.00% as of May. 2026. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 105932.1% on this metric.

Net margin is calculated as Net Income divided by its Revenue. CNBX Pharmaceuticals's Net Income for the three months ended in May. 2026 was $-0.15 Mil. CNBX Pharmaceuticals's Revenue for the three months ended in May. 2026 was $0.00 Mil. Therefore, CNBX Pharmaceuticals's net margin for the quarter that ended in May. 2026 was 0.00%.

The historical rank and industry rank for CNBX Pharmaceuticals's Net Margin % or its related term are showing as below:


CNBX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -78.87
* Ranked among companies with meaningful Net Margin % only.

CNBX Pharmaceuticals  (OTCPK:CNBX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

CNBX Pharmaceuticals Net Margin % Related Terms

CNBX Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals Net Margin % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -14,640.00 -904.88 -534.62 0.00

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNBX vs SIGY, LIPO, CARM: Net Margin % Comparison

For the Biotechnology subindustry, CNBX Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Net Margin % falls into.


CNBX Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CNBX Pharmaceuticals's Net Margin for the fiscal year that ended in Aug. 2025 is calculated as

Net Margin=Net Income (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-0.314/0
= %

CNBX Pharmaceuticals's Net Margin for the quarter that ended in May. 2026 is calculated as

Net Margin=Net Income (Q: May. 2026 )/Revenue (Q: May. 2026 )
=-0.154/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
CNBX Pharmaceuticals (CNBX) has a Net Margin % of 0.00% as of May. 2026. Net margin is the ratio of total net income to net sales. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry.
Is CNBX Pharmaceuticals' Net Margin % too high?
CNBX Pharmaceuticals' current Net Margin % is 0.00%. Based on the distribution chart, CNBX Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' Net Margin % compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 944 companies for Net Margin %. This places CNBX Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Net Margin % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.